Compare CANG & CNTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CANG | CNTN |
|---|---|---|
| Founded | 2010 | 2017 |
| Country | United States | United States |
| Employees | N/A | 3 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 170.4M | 184.2M |
| IPO Year | 2018 | 2022 |
| Metric | CANG | CNTN |
|---|---|---|
| Price | $0.42 | $3.23 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $3.00 | N/A |
| AVG Volume (30 Days) | ★ 1.2M | 429.9K |
| Earning Date | 05-13-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $428.72 | N/A |
| Revenue Next Year | $18.39 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.33 | $3.02 |
| 52 Week High | $5.75 | $5.27 |
| Indicator | CANG | CNTN |
|---|---|---|
| Relative Strength Index (RSI) | 36.74 | 35.92 |
| Support Level | $0.33 | $3.11 |
| Resistance Level | $0.77 | $3.51 |
| Average True Range (ATR) | 0.06 | 0.24 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 52.06 | 49.00 |
Cango Inc is a Bitcoin mining company with a vision to establish an integrated, world-wide infrastructure platform capable of powering the future digital economy. The Company's mining operations span over 40 sites across North America, the Middle East, South America, and East Africa. Since entering the digital asset space in November 2024, Cango has activated pilot projects in both integrated energy solutions and distributed AI computing. In parallel, Cango continues to operate an online international used car export business through its subsidiary.
Canton Strategic Holdings Inc is engaged in activities related to Canton Network, including the use of Canton Coin, to support blockchain-based infrastructure and the digitization of financial market processes. The company also operates a validator node on the Canton Network to facilitate transaction validation and network operations. It also operates a clinical-stage biotech research and development arm. Its flagship clinical asset, GV104, is being developed for a specific indication for respiratory and/or nervous system depression in military personnel and chemical incident responders. The expanded pipeline includes other indications for GV104 and GV023, an approach to autoimmune diseases as well as an early-stage multispecific biologic platform.